Antifungal drugs in pregnancy: A review

Expert Opinion on Drug Safety

Volumn 2, Issue 5, 2003, Pages 475-483

  Moudgal, Varsha V ^a   Sobel, Jack D ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Henry Ford Health System Division of Infectious Diseases   (United States)

Author keywords

amphotericin B; antifungals; azoles; Candida; clotrimazole; coccidioidomycosis; echinocandins; flucytosine; griseofulvin; miconazole; potassium iodide; pregnancy; sporotrichosis; terbinafine; vaginitis

Indexed keywords

ANTIFUNGAL AGENT;

CONGENITAL MALFORMATION; FEMALE; HUMAN; MYCOSIS; PREGNANCY; PREGNANCY COMPLICATION; REVIEW; RISK FACTOR;

ABNORMALITIES, DRUG-INDUCED; ANTIFUNGAL AGENTS; FEMALE; HUMANS; MYCOSES; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS;

EID: 2142666978     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2.5.475     Document Type: Review

References (79)

1. SOBEL JD: Use of antifungal drugs in pregnancy: a focus on safety. Drug Saf. (2000) 23:77-85. (Pubitemid 30455918)
2. CHOW AW, JEWESSON PJ: Pharmacokinetics and safety of antimicrobial agents during pregnancy. Rev. Infect. Dis. (1985) 7:287-313.
3. NATION RL: Drug kinetics in childbirth. Clin. Pharmacokinet. (1980) 5:340-364. (Pubitemid 10026852)
4. KRAUER B, KRAUER F: Drug kinetics in pregnancy. Clin. Pharmacokinet. (1977) 2:167-181. (Pubitemid 8137693)
5. FORFAR JO, NELSON MM: Epidemiology of drugs taken by pregnant women: drugs that may affect the fetus adversely. Clin. Pharmacol. Ther. (1973) 14:632-642.
6. MIRKIN BL: Perinatal pharmacology: placental transfer, fetal localization, and neonatal disposition of drugs. Anesthesiology (1975) 43:156-170.
7. FEDERAL REGISTER: (1980) 44:37434-37467.
8. SOBEL JD: Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am. J. Obstet. Gynecol. (1985) 152:924-935. (Pubitemid 15016406)
9. CATANZARO A: Pulmonary mycosis in pregnant women. Chest (1984) 86:S14-S18.
10. RODRIGUES J, NIEDERMAN MS: Pneumonia complicating pregnancy. Clin. Chest Med. (1992) 13:679-691.
11. VARTIVARIAN S, SMITH CB: Pathogenesis, host resistance, and predisposing factors. In: Candidiasis: pathogenesis, diagnosis, and treatment (2nd edn). Bodey GP (Ed.), Raven Press, New York (1993):59-84.
12. SOBEL JD: Genital candidiasis. In: Candidiasis: pathogenesis, diagnosis, and treatment (2nd edn). Bodey GP (Ed.), Raven Press, New York (1993):225-247.
13. HOPSU-HAVU VK, GRONROOS M, PUNNONEN R: Vaginal yeasts in parturients and infestation of the newborns. Acta Obstet. Gynecol. Scand. (1980) 59:73-77. (Pubitemid 10068567)
14. POWELL BL, FREY CL, DRUTZ DJ: Estrogen receptor in Candida albicans. A possible explanation for hormonal influences in vaginal candidiasis. 23rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, USA (1983). Abstract 751.
15. CARROLL CJ, HURLEY R, STANLEY VC: Criteria for diagnosis of candida vulvovaginitis in pregnant women. J. Obstet. Gynaecol. Br. Commonw. (1973) 80:258-263.
16. COTCH MF, HILLIER SL, GIBBS RS, ESCHENBACH DA: Epidemiology and outcomes associated with moderate to heavy candida colonization during pregnancy. Vaginal infections and prematurity study group. Am. J. Obstet. Gynecol. (1998) 178:374-380. (Pubitemid 28124143)
17. MAZOR M, CHAIM W, SHINWELL ES, GLEZERMAN M: Asymptomatic amniotic fluid invasion with Candida albicans in preterm premature rupture of membranes. Implications for obstetric and neonatal management. Acta Obstet. Gynecol. Scand. (1993) 72:52-54. (Pubitemid 23074906)
18. DONDERS GG, MOERMAN P, CAUDRON J, VAN ASSCHE FA: Intra-uterine candida infection: a report of four infected fetuses from two mothers. Eur. J. Obstet. Gynecol. Reprod. Biol. (1991) 38:233-238.
19. SHALEV E, BATTINO S, ROMANO S, BLONDHAIM O, BEN-AMI M: Intraamniotic infection with Candida albicans successfully treated with transcervical amnioinfusion of amphotericin. Am. J. Obstet. Gynecol. (1994) 170:1271-1272. (Pubitemid 24188688)
20. PAPPAGIANIS D: Epidemiology of coccidiodomycosis. In: Coccidiodomycosis. A text. Stevens D (Ed.), Plenum Medical Book Company, New York (1980):63-85.
21. ELEWSKI BE: Superficial mycosis, dermatophytoses, and selected dermatomycosis. In: Topics in clinical dermatology; cutaneous fungal infections. Elewski BE (Ed.), Igaku-shoin Medical Publishers, New York (1992):12-68.
22. KING CT, ROGERS PD, CLEARY JD, CHAPMAN SW: Antifungal therapy during pregnancy. Clin. Infect. Dis. (1998) 27:1151-1160. (Pubitemid 29242465)
23. BRIGGS GG FR, YAFFE SJ: Drugs in pregnancy: a reference guide to fetal and neonatal risk (6th edn). Briggs GG, Yaffe J (Eds), Lippincott Williams and Wilkins, USA (2002).
24. PRODUCT INFORMATION: Lamisil. Novartis (2001).
25. GULL K, TRINCI AP: Griseofulvin inhibits fungal mitosis. Nature (1973) 244:292-294.
26. ROSA FW, HERNANDEZ C, CARLOWA: Griseofulvin teratology, including two thoracopagus conjoined twins. Lancet (1987) 1:171. (Pubitemid 17015867)
27. KNUDSEN LB: No association between griseofulvin and conjoined twinning. Lancet (1987) 2:1097.
28. DIFLUCAN PACKAGE INSERT: New York. Roerig Division, Pfizer (2003).
29. LEE BE, FEINBERG M, ABRAHAM JJ, MURTHY AR: Congenital malformations in an infant born to a woman treated with fluconazole. Pediatr. Infect. Dis. J. (1992) 11:1062-1064.
30. PURSLEY TJ, BLOMQUIST IK, ABRAHAM J, ANDERSEN HF, BARTLEY JA: Fluconazole-induced congenital anomalies in three infants. Clin. Infect. Dis. (1996) 22:336-340. (Pubitemid 26056165)
31. ALECK KA, BARTLEY DL: Multiple malformation syndrome following fluconazole use in pregnancy: report of an additional patient. Am. J. Med. Genet. (1997) 72:253-256. (Pubitemid 27424225)
32. MASTROIACOVO P, MAZZONE T, BOTTO LD et al.: Prospective assessment of pregnancy outcomes after first-trimester exposure to fluconazole. Am. J. Obstet. Gynecol. (1996) 175:1645-1650. (Pubitemid 27021041)
33. JICK SS: Pregnancy outcomes after maternal exposure to fluconazole. Pharmacotherapy (1999) 19:221-222. (Pubitemid 29072033)
34. TAN CG, GOOD CS, MILNE LJ, LOUDON JD: A comparative trial of six day therapy with clotrimazole and nystatin in pregnant patients with vaginal candidiasis. Postgrad. Med. J. (1974) 50(Suppl. 1):102-105.
35. DAVIS JE, FRUDENFELD JH, GODDARD JL: Comparative evaluation of monistat and mycostatin in the treatment of vulvovaginal candidiasis. Obstet. Gynecol. (1974) 44:403-406.
36. HIGTON BK: A trial of clotrimazole and nystatin in vaginal candidiasis. Postgrad. Med. J. (1974) 50(Suppl. 1):95-98.
37. MCNELLIS D, MCLEOD M, LAWSON J, PASQUALE SA: Treatment of vulvovaginal candidiasis in pregnancy. A comparative study. Obstet. Gynecol. (1977) 50:674-678. (Pubitemid 8237048)
38. ABRAMS LS, WEINTRAUB HS: Disposition of radioactivity following intravaginal administration of 3h-miconazole nitrate. Am. J. Obstet. Gynecol. (1983) 147:970-971. (Pubitemid 14208297)
39. PRODUCT INFORMATION: Monistat. Ortho Pharmaceutical (1991).
40. ROSA FW, BAUM C, SHAW M: Pregnancy outcomes after first-trimester vaginitis drug therapy. Obstet. Gynecol. (1987) 69:751-755. (Pubitemid 17057835)
41. RITTER W: Pharmacokinetic fundamentals of vaginal treatment with clotrimazole. Am. J. Obstet. Gynecol. (1985) 152:945-947. (Pubitemid 15016409)
42. FRERICH W, GAD A: The frequency of candida infections in pregnancy and their treatment with clotrimazole. Curr. Med. Res. Opin. (1977) 4:640-644. (Pubitemid 8112873)
43. HARAM K, DIGRANES A: Vulvovaginal candidiasis in pregnancy treated with clotrimazole. Acta Obstet. Gynecol. Scand. (1978) 57:453-455. (Pubitemid 9030450)
44. NO AUTHORS LISTED: Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm. Rep. (2002) 51:1-78.
45. SOBEL JD, FARO S, FORCE RW et al.: Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am. J. Obstet. Gynecol. (1998) 178:203-211. (Pubitemid 28124116)
46. ROMIG DA, VOTH DW, LIU C: Facial sporotrichosis during pregnancy. A therapeutic dilemma. Arch. Intern. Med. (1972) 130:910-912.
47. VANDERVEEN EE, MESSENGER AL, VOORHEES JJ: Sporotrichosis in pregnancy. Cutis (1982) 30:761-763. (Pubitemid 13223557)
48. WOLFF J: Iodide goiter and the pharmacologic effects of excess iodide. Am. J. Med. (1969) 47:101-124.
49. CARSWELL F, KERR MM, HUTCHISON JH: Congenital goitre and hypothyroidism produced by maternal ingestion of iodides. Lancet (1970) 1:1241-1243.
50. MEHTA PS MS, VORHERR H: Congenital iodide goitre and hypothyroidism: a review. Obstet. Gynecol. Surv. (1983) 38:237-247. (Pubitemid 15152278)
51. PRODUCT INFORMATION: Ancobon. Roche laboratories (2003).
52. DIASIO RB, LAKINGS DE, BENNETT JE: Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity. Antimicrob. Agents Chemother. (1978) 14:903-908. (Pubitemid 9074641)
53. PHILPOT CR, LO D: Cryptococcal meningitis in pregnancy. Med. J. Aust. (1972) 2:1005-1007.
54. SCHONEBECK J, SEGERBRAND E: Candida albicans septicaemia during first half of pregnancy successfully treated with 5-fluorocytosine. Br. Med. J. (1973) 4:337-338.
55. CUROLE DN: Cryptococcal meningitis in pregnancy. J. Reprod. Med. (1981) 26:317-319.
56. PRODUCT INFORMATION: Nizoral. Janssen Pharmaceuticals (2003).
57. SONINO N: The use of ketoconazole as an inhibitor of steroid production. N. Engl. J. Med. (1987) 317:812-818. (Pubitemid 17133360)
58. HEEL RC, BROGDEN RN, CARMINE A et al.: Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs (1982) 23:1-36. (Pubitemid 12133574)
59. MCGREGOR JA, PONT A: Contraindication of ketoconazole in pregnancy. Am. J. Obstet. Gynecol. (1984) 150:793-794. (Pubitemid 15204669)
60. AMADO JA, PESQUERA C, GONZALEZ EM et al.: Successful treatment with ketoconazole of cushing's syndrome in pregnancy. Postgrad. Med. J. (1990) 66:221-223. (Pubitemid 20083082)
61. TIBONI GM: Second branchial arch anomalies induced by fluconazole, a bis-triazole antifungal agent, in cultured mouse embryos. Res. Commun. Chem. Pathol. Pharmacol. (1993) 79:381-384. (Pubitemid 23095812)
62. SPORANOX PACKAGE INSERT: Nutley, NJ. Roche laboratories (2003).
63. BAR-OZ B, MORETTI ME, BISHAI R et al.: Pregnancy outcome after in utero exposure to itraconazole: a prospective cohort study. Am. J. Obstet. Gynecol. (2000) 183:617-620.
64. PRODUCT INFORMATION: Voriconazole. Pfizer Pharmaceuticals (2003).
65. DEAN JL, WOLF JE, RANZINI AC, LAUGHLIN MA: Use of amphotericin B during pregnancy: case report and review. Clin. Infect. Dis. (1994) 18:364-368. (Pubitemid 24086306)
66. COHEN I: Absence of congenital infection and teratogenesis in three children born to mothers with blastomycosis and treated with amphotericin B during pregnancy. Pediatr. Infect. Dis. J. (1987) 6:76-77. (Pubitemid 17229316)
67. ISMAIL MA, LERNER SA: Disseminated blastomycosis in a pregnant woman: review of amphotericin B usage during pregnancy. Am. Rev. Respir. Dis. (1982) 126:350-353. (Pubitemid 12047103)
68. HOBERMAN AM FJ, MARTIN T et al.: Developmental toxicity studies of amphocil (tm) administered intravenously to Sprague-Dawley rats and new zealand white rabbits. Toxicologist (1994) 14:160.
69. REX JH, WALSH TJ, SOBEL JD et al.: Practice guidelines for the treatment of candidiasis. Infectious diseases society of America. Clin. Infect. Dis. (2000) 30:662-678.
70. ABELCET PACKAGE INSERT: Princeton, NJ. The Liposome Company (2003).
71. AMBISOME PACKAGE INSERT: San Dimas, CA. Nextar Pharmaceuticals (2003).
72. AMPHOTEC PACKAGE INSERT: Menlo Park, CA. Sequus Pharmaceuticals (2003).
73. GRADONI L, GAETA GB, PELLIZZERG, MAISTO A, SCALONE A: Mediterranean visceral leishmaniasis in pregnancy. Scand. J. Infect. Dis. (1994) 26:627-629. (Pubitemid 24321311)
74. ONISHI J, MEINZ M, THOMPSON J et al.: Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors. Antimicrob. Agents Chemother. (2000) 44:368-377. (Pubitemid 30060733)
75. DENNING DW: Echinocandins: a new class of antifungal. J. Antimicrob. Chemother. (2002) 49:889-891. (Pubitemid 34692881)
76. ERNST EJ, ROLING EE, PETZOLD CR, KEELE DJ, KLEPSER ME: In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies. Antimicrob. Agents Chemother. (2002) 46:3846-3853. (Pubitemid 35403260)
77. BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46:3001-3012.
78. MAERTENS JR, SABLE CA et al.: Multicenter, noncomparative study to evaluate safety and efficacy of caspofungin in adults with invasive Aspergillosis refractory to amphotericin B, amphotericin B lipid formulations, or azoles. Abstracts of the 40th International Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, DC, USA (2000). Abstract 1103, 371.
79. CANCIDAS PACKAGE INSERT: Merck Laboratories (2002).